The burden of high drug costs is something that everyone with health insurance coverage is facing, explained Leigh Purvis, director, Health Services Research, AARP Public Policy Institute.
The burden of high drug costs is something that everyone with health insurance coverage is facing, explained Leigh Purvis, director, Health Services Research, AARP Public Policy Institute.
Transcript
How does the burden of high prescription drug costs in Medicare have a broader impact than just on Medicare beneficiaries?
This problem is not unique to Medicare. This is something that everyone who has health insurance coverage is facing, and frankly, all Americans are facing. A message we always like to drive home when it comes to prescription drug costs is that it’s an issue that affects everyone. You’re either paying for them at the pharmacy counter, you’re paying for them as part of your premiums or part of your cost-sharing as someone with health coverage, or you’re paying for them through your taxes. Programs like Medicare and Medicaid are spending a lot of money of these products, and that eventually will translate into taxes, and ultimately can turn into either higher taxes or cuts to the programs that people rely on.
How does the drug cost burden facing the US elderly population compare with the elderly population in other, similar countries?
I think high prescription drug costs are a challenge globally, but I think they’re much more so in the United States. We face much higher cost-sharing, we have higher cost-related non-adherence. Just the nature of the health coverage system in the United States is much more fragmented. It makes it harder for them to drive bargains on prices that other countries are able to do just by virtue of the fact that they’re bargaining on the behalf of everyone.
In VERIFY, Rusfertide Spares Most Patients With PV a Phlebotomy for 32 Weeks, Improves QOL
June 3rd 2025Adding rusfertide to standard of care more than doubled the share of patients with polycythemia vera (PV) who did not meet criteria for a phlebotomy, according to data from the VERIFY trial.
Read More
Laundromats as a New Frontier in Community Health, Medicaid Outreach
May 29th 2025Lindsey Leininger, PhD, and Allister Chang, MPA, highlight the potential of laundromats as accessible, community-based settings to support Medicaid outreach, foster trust, and connect families with essential health and social services.
Listen
New Research Challenges Assumptions About Hospital-Physician Integration, Medicare Patient Mix
April 22nd 2025On this episode of Managed Care Cast, Brady Post, PhD, lead author of a study published in the April 2025 issue of The American Journal of Managed Care®, challenges the claim that hospital-employed physicians serve a more complex patient mix.
Listen
Trastuzumab Deruxtecan Plus Pertuzumab Improves PFS vs Standard Care in HER2+ Breast Cancer
June 2nd 2025Trastuzumab deruxtecan plus pertuzumab demonstrated statistically and clinically significant improvement in progression-free survival (PFS) in HER2-positive breast cancer, potentially representing a new standard of care.
Read More
Multicancer Detection Assays Remain Largely Elusive for Early-Stage Disease Detection
June 1st 2025Multicancer early detection tests are revolutionizing cancer screening by using liquid biopsies to screen for multiple cancers from a single blood sample, enhancing patient outcomes by identifying cancers earlier.
Read More